A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Inclusion Criteria:

For Patients:

Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration:

• Patients must be 18 years of age or older.

• IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LBAML or CMML (with symptoms), as confirmed by recent full blood examination, bonemarrow biopsy, and cytogenetic testing. NOTE: IPSS-R defined intermediate MDSpatients are limited to less than 50% of enrolled patients.

• Life expectancy of at least 6 months.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 inclusive.

• Patient must be able to co-operate and complete tasks (including tasks such aselectronic questionnaires on digital devices) over the following 4 months.

Inclusion Criteria:

For Patients:

Patients are eligible to be included in the study only if all of the following criteria apply at any time starting from Screening up to Day 1 prior to study treatment administration:

• Patients must be 18 years of age or older.

• IPSS-R defined intermediate MDS, IPSS defined intermediate 2 or high-risk MDS, LBAML or CMML (with symptoms), as confirmed by recent full blood examination, bonemarrow biopsy, and cytogenetic testing. NOTE: IPSS-R defined intermediate MDSpatients are limited to less than 50% of enrolled patients.

• Life expectancy of at least 6 months.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 inclusive.

• Patient must be able to co-operate and complete tasks (including tasks such aselectronic questionnaires on digital devices) over the following 4 months.

• Patient must be able to identify a carer to participate in completing the cTPMQ.

For Carers:

• Primary carer of a patient meeting all of the inclusion criteria (ie, a patient who meets criteria defined above).

For Clinicians:

• Clinician treating patients meeting all of the inclusion criteria (ie, treats patients who meet criteria defined above).

Exclusion Criteria:

For Patients:

Patients are excluded from the study if any of the following criteria apply:

• Patients with known hypersensitivity to the study treatments oraldecitabine/cedazuridine or azacitidine.

• Patients with advanced malignant hepatic tumors.

• Patients with severe renal impairment (creatinine clearance <30 mL/min).

• Patients who have received hypomethylating agents (HMA) previously.

• Patients who are receiving lenalidomide or are receiving other therapies outside ofstandard of care (SOC).

• Receipt of any immunotherapy, any conventional or investigational systemicanti-cancer therapy within 5 half-lives of the drug, or within 4 weeks prior to thefirst dose of study treatment (whichever is longer).

• Any medical, psychological, social, or other condition which in the view of theInvestigator is likely to interfere with the study, compliance, or put the patientat risk.

• Participants who are not fluent in English, or who cannot read or write in Englishwill be excluded from the study.

For Carers:

Carers are excluded from the study if any of the following criteria apply:

• They are a carer of a patient who meets any of the exclusion criteria listed above.

• They are a relative of an employee of the investigational clinic or sponsor (e.g.Investigator, study coordinator)

For Clinicians:

• Clinicians will be excluded from participating in the study if they are a relative of an employee of the investigational clinic or sponsor (e.g. Investigator, Study Coordinator).